The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | Epigenetic mechanisms and durability of response in CLL
Carmela Dell’Aversana, PhD, LUM University, Bari, Italy, discusses how targeting epigenetic mechanisms in chronic lymphocytic leukemia (CLL) may improve depth and durability of response. She explores how reversible epigenetic modulation could help overcome resistance and contribute to more sustained disease control in heterogeneous patient populations. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
